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Abstract Ecotin, a serine protease inhibitor found in the peri- 
plasm of Escherichia coli, has been characterized as a potent 
reversible tight-binding inhibitor of the human contact activation 
proteases factor XIIa (FXIIa) and plasma kallikrein, having K i 
values of 89 pM and 163 pM, respectively. Ecotin also inhibited 
human leukocyte lastase (HLE) with high affinity (Ki = 55 pM). 
The association rate constants ko, for FXIIa and kallikrein were 
5.3 × l0 s M -t .s -1 and 2.9 × 105 M -1 "s -~, respectively. The dis- 
sociation rate constant kon for kallikrein, measured in the pres- 
ence of HLE to prevent reassociation, was 6.3 × 10 -s s-~; the koff 
for ecotin with FXIIa was 4.7 x 10 -s s -~. Both FXIIa and kal- 
likrein cleaved ecotin slowly at pH 5.0, identifying Met-84 as the 
P~ residue. The potent anticoagulant effect by ecotin is explained 
by the coincident inhibition of FXIIa, kallikrein, and FXa and 
suggests that it may be useful in the study of inflammatory or 
thrombotic disorders such as sepsis or cardiopulmonary bypass. 
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I. Introduction 
Contact activation isa surface mediated pathway responsible 
in part for the regulation of both inflammation and coagulation 
[1,2]. The proteins involved in this pathway include factor XII 
(Hageman factor), prekallikrein (Fletcher factor), high molecu- 
lar weight kininogen (HMWK), factor XI, and C1 inhibitor. It 
has been suggested that this plasma protease system plays a 
significant role in a variety of clinical states including septic 
shock, adult respiratory distress yndrome, cardiopulmonary 
bypass, disseminated intravascular coagulation (DIC), and he- 
reditary angioedema [3,4]. Inhibitors of the contact system may 
therefore play important roles in the regulation of inflamma- 
tory and/or thrombotic disorders. 
Factor XII is the first zymogen in the intrinsic pathway of 
blood coagulation and is converted to its active serine protease 
factor XIIa (FXIIa) in plasma by exposure to negatively 
charged surfaces uch as glass, connective tissue or collagen, 
endotoxin, and a wide variety of other endogenous or ex- 
ogenous components. In the presence of HMWK, FXIIa can 
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activate prekallikrein to kallikrein and factor XI to factor Xla; 
the kallikrein formed can activate more factor XII to FXIIa. 
Factor XIa generates factor IXa, which in the presence of 
factor VIIIa leads to the formation of factor Xa (FXa) and 
thrombin and ultimately results in the formation of a fibrin clot. 
In addition to the reciprocal feedback activation of surface 
bound factor XII to FXIIa, plasma kallikrein cleaves HMWK 
to form bradykinin, a potent endogenous vasodilator, and can 
activate prourokinase. Both factor XIIa and kallikrein have 
also been implicated in neutrophil degranulation, regulation of 
the complement pathway, and plasminogen activation [1,2]. A 
simplified scheme of the contact activation system leading to 
inflammation and coagulation is shown in Fig. 1. 
Protein inhibitors of proteases play critical roles in the regu- 
lation of proteolytic activity in a wide variety of physiological 
processes. They have been extensively studied from functional, 
structural, and mechanistic perspectives [5,6]. Ecotin has been 
previously characterized asa periplasmic protein in E. coli and 
an inhibitor of the pancreatic serine proteases trypsin and chy- 
motrypsin (bovine), porcine elastase, as well as rat mast cell 
chymase [7-9]. More recently, we have shown that ecotin is a 
very potent anticoagulant and reversible tight-binding inhibitor 
of human FXa with a Ki of 54 pM [10]. In this report, we show 
that ecotin is also a very potent reversible inhibitor of the 
human contact activation proteases FXIIa and plasma kal- 
likrein as well as human leukocyte lastase (HLE). 
2. Materials and methods 
2.1. Materials 
Ecotin was purified from the periplasm of cultures of E. coli 27C7 
transformed with the ecotin expression plasmid as previously described 
[10]. Human FXIIa and human plasma kallikrein were obtained from 
Enzyme Research Labs. Inc. (South Bend, IN). Human leukocyte las- 
tase was purchased from Elastin Products Co. Bovine trypsin, Triton 
X-100, and N-MeOSuc-Ala-Ala-Pro-Val-7-amido-4-methyl-coumarin 
(AAPV-MCA) were from Sigma. $2302 (H-D-Pro-Phe-Arg- 
pNA.2HC1) was obtained from Chromogenix and Spec- 
trozyme P.Kal (H-D-prolyl-hexahydrotyrosyl-arginine-p-nitroanili 
de. diacetate) was from American Diagnostica. Poly- 
acrylamide gels were purchased from Novex; molecular weight stan- 
dards were from LKB (horse myoglobin peptides) and Novex (Mark 
12). All other eagents were of the highest grade commercially available. 
2.2. Determination of equilibrium dissociation constants 
Enzyme inhibition assays were conducted in a microtiter format 
using equipment and analytical methods previously described [10]. 
Ecotin quantitation was carried out by active site titration using N °- 
benzoyl-L-arginine-p-nitroanilide (Bachem) and trypsin; 4-methylum- 
belliferyl p-guanidinobenzoate (Sigma) was used to burst itrate trypsin 
[lO]. 
FXlIa or kallikrein was quantitated by active site titration using 
ecotin as a standard and 0.5 mM $2302 as a substrate, assuming a 1 : 1 
complex formation [7,10]; HLE was quantitated by the method of 
Beatty et al. [11]. There was good agreement between protein concen- 
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trations determined by active site titrations and the manufacturer's 
stated concentration. The Km for $2302 with FXIIa and kallikrein 
under the conditions used for each enzyme was 125/2M and 165/2M, 
respectively; the Km for AAPV-MCA with HLE was 150/2M. 
Apparent K~ values (K~*) for the inhibition of FXIIa and plasma 
kallikrein by ecotin were measured as follows. Human FXIIa (1.6 or 
12.5 nM final concentration) was incubated with quantitated ecotin 
(0-80 nM final concentration) i  buffer A (50 mM Tris, pH 7.5, 20 mM 
NaC1, and 0.005% Triton X-100) containing 2 mM CaCI2, in a total 
volume of 180/21. After 1 h at room temperature to allow equilibration 
of the enzyme, inhibitor complex, 20/21 of 5 mM $2302 was added and 
the change in absorbance at405 nm was monitored. The K~* for ecotin 
with kallikrein was determined in a similar manner with kallikrein (1.3 
nM or 4.3 nM final concentration) and 0-16 nM ecotin. The K~* for 
ecotin with HLE (0.9 nM or 2.1 nM final concentration) was deter- 
mined in 0.1 M Tris-HCl, pH 7.5, 0.5 M NaC1 and 0.005% Triton 
X-I00. After incubation at room temperature for 2 h, AAPV-MCA (80 
/2M final concentration) was added and the change in fluorescence was 
monitored on a Labsystems Fluoroskan II plate reader with excitation 
at 355 nm and emission at 460 nm. The kinetic data from each experi- 
ment were fit to Eqn. 1: 
KlVo = 
1 + [Io]/[Eo] + Ki*/[Eo] - -~  + [Io]/[Eo] + K,*I[Eo]) 2 - (4 × [Io]/[Eo]) 
1 
(t) 
where V~ Vo is the fractional activity (steady-state inhibited rate divided 
by the uninhibited rate), [Eo] is the total enzyme concentration, and [Io] 
is the total ecotin concentration. Values for K~* were determined by 
non-linear regression analysis. 
2.3. Determination of association rate constants 
The association rates of ecotin with FXIIa and kallikrein were deter- 
mined as follows. At reference time zero, ecotin (14 nM final concentra- 
tion) was added to FXIIa (10 nM final concentration) and buffer A 
containing 2 mM CaCI2 in a total volume of 4.0 ml. Immediately 
thereafter, 150/21 aliquots were removed at intervals over a period of 
10 min and added to microtiter wells containing 50/21 of 5 mM $2302. 
For kallikrein, ecotin (7 nM final concentration) was added to kal- 
likrein (5 nM final concentration) and buffer A in a total volume of 3.0 
ml at reference time zero. Immediately thereafter, 150 ,ul aliquots were 
removed at intervals over a period of 10 rain and added to microtiter 
wells containing 50/21 of 2.5 mM Spectrozyme P.Kal. The absorbance 
was monitored at 405 nM and initial rates were determined for each well 
using the initial linear portion of each data set. The rate constants were 
determined by measuring free enzyme as a function of time and fitting 
the data to Eqn. 2: 
[lo] x [Eo] x (el([[ol-[%]l x ko~ TM - l) 
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Fig. 1. Simplified scheme of the contact activation system. The serine 
proteases potently inhibited by ecotin are boxed and shaded. Biological 
consequences of contact activation are in italics. 
where [E] is the concentration of free enzyme at any time t and [Eo] 
and [Io] represent the initial concentrations of enzyme and inhibitor, 
respectively. Values for ko, were determined by non-linear regression 
analysis. 
2.4. Determination of dissociation rate constant 
The dissociation rate constant of the ecotin, kallikrein complex was 
measured using HLE to trap the free ecotin released from the complex. 
Kallikrein (2.4/2M) was incubated at room temperature for 1 h in buffer 
A in the presence and absence of equimolar ecotin and then at reference 
time zero, an aliquot was diluted 100-fold into buffer A with and 
without HLE (410 nM). Aliquots (150/21) were removed at various 
times and added to 50/21 of 2.5 mM Spectrozyme P.Kal. Initial rates 
were measured at 405 nm and product curve data (free enzyme vs. time) 
were fit to Eqn. 3: 
[E] = [EI]0 x (1 - e -kon- × ') (3) 
where [E] is the free [kaUikrein] at any time t, [E x I]0 is the concentra- 
tion of the complex at time zero, and koff is the first-order dissociation 
rate constant. Values for koff were determined by non-linear regression 
analysis. 
2.5. Active site determination of ecotin by cleavage with FXIIa and 
kallikrein 
In order to determine if and where ecotin is cleaved by FXIIa or 
kallikrein, ecotin (81.3/2M) and enzyme (3.1 tiM) were co-incubated in 
100 mM NaOAc pH 5.0, 50 mM CaC12. After 48 h, aliquots of the 
reaction mixture were removed and subjected to SDS-PAGE on 16% 
Tricine gels. These gels were then electroblotted onto polyvinylidene 
difluoride (PVDF) membranes, the membranes were stained for 30 s 
in 0.1% Coomassie blue R-250 in 50% methanol, destained, and the 
bands of interest excised and sequenced as previously described [10]. 
3. Results and discussion 
3.1. Determination of  equilibrium dissociation constants 
Apparent  equil ibrium dissociation values (Ki*) were deter- 
mined using methods derived for t ight-binding inhibitors since 
there was substantial inhibit ion at concentrations of ecotin 
comparable to that of the protease [12,13]. The inhibit ion of 
FXIIa,  kallikrein and HLE by ecotin under equil ibrium condi- 
tions is shown in Fig. 2. If the inhibitor and substrate compete 
for the same active site which is almost certainly true since 
ecotin is cleaved by the enzyme (see below), the true K~ value 
is generally related to Ki* by the expression Ki = Ki*/(1 + 
[S]/K m), where Km is the Michaelis constant for substrate [14]. 
However, since ecotin.enzyme complex dissociation is negligi- 
ble during the assay (see below), the Ki* for ecotin is equal to 
the true K~. In this manner, K i values of 89 pM and 163 pM were 
calculated for ecotin binding to FXI Ia  and kallikrein, respec- 
tively (Table 1). The Ki for ecotin with kallikrein of 163 pM 
measured under equil ibrium conditions is in very good agree- 
ment with the K~ measured kinetically where the ratio of konlkon 
is 217 pM (see below). The Ki value for ecotin with HLE was 
55 pM (Table 1); this is about  24-fold higher affinity than has 
been reported for ecotin with porcine pancreatic elastase [9]. 
Based on active site titrations with ecotin concentrations 
>100 x K~, the interaction with FXI Ia,  kallikrein and HLE 
was stoichiometric, i.e. a 1 : 1 molar ratio of enzyme-to-ecotin 
was found for the E. I complexes formed. We previously dem- 
onstrated that ecotin exists primarily as a dimer at concentra- 
tions above -390  nM and that the ecotin. FXa complex consists 
of one ecotin dimer and two FXa  molecules [10]. In addition, 
the trypsin, ecotin complex has also been shown by biochemical 
methods [7] and by X-ray crystal lography [15] to consist of one 
ecotin dimer and two trypsin molecules. By analogy, we postu- 
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Fig. 2. Determination of the apparent equilibrium dissociation con- 
stants of ecotin with factor XIIa, kallikrein, and HLE. The K*~ values 
were determined by non-linear regression analysis of the data using 
Eqn. 1; the curves represent the fractional activity determined from 
equation 1 using the calculated K*i values. The calculated K* values 
for factor XIIa (z~), kallikrein (*), and HLE (o) were 101 pM, 168 pM, 
and 80 pM, respectively; the enzyme concentrations were 12.5 nM, 
1.3 nM, and 2.1 nM, respectively. 
late that inhibition by ecotin at high concentrations involves 
one ecotin dimer with two protease molecules. The equations 
used to calculate the various kinetic constants assume that the 
complex contains one molecule ach of enzyme and inhibitor. 
These equations are appropriate since the equilibrium and ki- 
netic measurements were conducted at a concentration range 
well below the Kd for ecotin dimerization. 
3.2. Determination fassociation and dissoc&tion rate constants 
The rate of association ofecotin with FXIIa or kallikrein was 
measured uring the initial phase of the reaction, where disso- 
ciation of the E. I complex is negligible, and the rate constants 
were calculated from the integrated form of the second-order 
rate equation [10]. The association of ecotin with FXIIa and 
kallikrein is rapid with association rate constants (ko,) of 
5.3 x 105 M- l 's  -1 and 2.9x 105 M-l-s -1, respectively (Fig. 3; 
Table l). 
Because the affinity of ecotin for kallikrein is so high, the rate 
of dissociation of the ecotin, kallikrein complex was measured 
after a 100-fold dilution into buffer containing a 17-fold molar 
excess of HLE. Ecotin binds with high affinity to HLE (Table 
1), which was used to trap free ecotin and prevent i s reassoci- 
ation with kallikrein. In the absence of HLE, reassociation of
Table 1 
Equilibrium dissociation and kinetic constants for ecotin with factor 
XIIa, plasma kallikrein, HLE and factor Xa" 
Enzyme Ki (pM) kon × 10 -5 ko,× 105 (s -t) 
(M -]" s l) 
FactorXlla 89+51 (n=5) 5.3+0.3 (n=3) 4.7 b 
Plasma kallikrein 163 + 24 (n = 6) 2.9 + 0.1 (n = 4) 6.3; 4.7 b 
HLE 55 + 23 (n = 3) n.d5 n.d5 
FXa d 54 13.5 6.5 
"The number of independent determinations is indicated in brackets. 
bValues in parenthesis are calculated from (K 0 × (kon). Cn.d. = not 
determined, Taken from Seymour et al. [10]. 
ecotin with kallikrein was so rapid that free kallikrein was 
barely detectable. Progress of dissociation was monitored as the 
increase in hydrolysis rate of Spectrozyme P.Kal, which is not 
hydrolyzed by HLE, resulting from the increase in free enzyme 
with time (Fig. 4). A control acking ecotin showed that the 
specific activity of kallikrein (74 OD405 min -~. nmol-') was un- 
affected by the presence of HLE over the time course of 
the experiment. The time dependent dissociation of the 
ecotin.kallikrein complex was fit to Eqn. 3; the value 
for kof is 6.3 × 10 -5 s -1 (Table 1). 
We were unable to measure a dissociation constant for ecotin 
with FXIIa since reassociation of ecotin with FXIIa was so 
rapid that free FXIIa was barely detectable. HLE inactivated 
FXIIa and could therefore not be used to measure the dissoci- 
ation rate by trapping free ecotin. The dissociation rate con- 
stant of ecotin with FXIIa as calculated from ko, x K~ is 
4.7 x 10 -5 s-' (Table 1). 
Based on activated partial thromboplastin me (APTT) clot- 
ting assays, approximately 300 nM ecotin is required to prolong 
the clotting time 10-fold [10]; at this concentration, the interac- 
tion of ecotin with FXIIa and kallikrein is essentially irreversi- 
ble since the K~ is much less than the ecotin concentration [16]. 
The slow dissociation rates predict a half-life for the E-I com- 
plexes of ca. 3 h. Furthermore, the association rates are rela- 
tively rapid, suggesting that ecotin could play a significant role 
in vivo. However, it is difficult o predict he relative degree of 
inhibition of each enzyme where many other factors may con- 
tribute to these interactions. 
3.3. Reactive site determination of ecot& with Jactor XIIa and 
plasma kallikrein 
The interaction of ecotin with FXIIa and kallikrein results 
in a slow cleavage of the inhibitor by the enzyme under certain 
in vitro conditions. Fig. 5 illustrates the amount of cleavage of 
ecotin by FXIIa and kallikrein at pH 5.0 in 48 hours. The 
N-terminal sequences obtained (Fig. 5) revealed that both 
FXIIa and kallikrein slowly cleave ecotin between Met-84 and 
Met-85. These results define Met-84 as the PL residue [17] which 
agrees with studies using trypsin, chymotrypsin, and porcine 
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Fig. 3. Determination of ecotin association rates with factor X l la  and 
kallikrein. The association rate constants for ecotin were determined 
by nonlinear regression analysis of the data using Eqn. 2; the curves 
represent the free enzyme concentration determined from Eqn. 2 using 
the calculated ko, values. The data shown yielded ko, values of 5.6 × 105 
M-' 's-' for FXIIa (/x) and 2.9 x 105 M -~ .s -~ for kallikrein (*). 













0 15 20 
Fig. 4. Determination fecotin dissociation rate with kallikrein. The 
dissociation ofecotin from kallikrein in the presence ofriLE to prevent 
reassociation is shown (*). The curve results from non-linear regression 
analysis of the data fit to equation 3using the calculated ko~- value of 
6.3 x 10 -5 s -~, where the measured velocity is proportional to free en- 
zyme. 
pancreatic elastase [8] and FXa [10]. In studies with these pro- 
teases, the replacement of the PI methionine r sidue with vari- 
ous sidechains led to mutants that were still potent inhibitors 
[9,18], suggesting that residues other than P~ significantly con- 
tributed to binding. The X-ray crystal structure of the 
ecotin.trypsin complex has shown that a second dis- 
crete and distal binding site exists [15]. 
3.4. Anticoagulant properties 
We previously demonstrated that ecotin is a potent anticoag- 
ulant as assessed by both APTT and prothrombin time (PT) 
assays; a 10-fold prolongation of clotting times was found at 
concentrations of ca. 0.3 pM and ca. 2 pM, respectively [10]. 
The prolonged clotting times are consistent with inhibition of 
FXa; however, the greater potency observed in the APTT 
assay, which measures intrinsic coagulation pathway activa- 
tion, likely reflects the additional inhibition of the contact acti- 
vation proteases FXIIa and plasma kallikrein. Thus, the coinci- 
dent inhibition of FXa, FXIIa, and kallikrein by ecotin leads 
to a more potent anticoagulant effect than one due to the 
inhibition of FXa alone. 
3.5. Other inhibitors of contact activation proteases 
The contact system is primarily regulated by C1 inhibitor, a
naturally occurring human protein inhibitor belonging to the 
serpin family of protease inhibitors. C1 inhibitor binds irrevers- 
ibly to FXIIa and kallikrein and is the primary physiological 
inhibitor of both of these proteases; ~z-macroglobulin is an- 
other significant inhibitor of kallikrein [1,2]. In the presence of 
heparin, antithrombin-III can inhibit FXIIa and kallikrein; 
however, it inhibits thrombin and factor Xa (FXa) more effec- 
tively. Kallikrein and factor XIIf, a 30 kDa fragment contain- 
ing the serine protease domain of FXII, are more potently 
inhibited by a mutant form of ~-proteinase inhibitor contain- 
ing an arginine in the P~ position than by C1 inhibitor 
[19,201. 
A number of other exogenous protein inhibitors of FXIIa 
and kallikrein have been previously identified, although none 
bind with the very high affinity of ecotin. Curcurbita maxima 
trypsin inhibitor III (CMTI III) is a 29 amino acid protease 
inhibitor containing 3 disulfide bonds isolated from squash 
seeds which inhibits FXIIa with a K~ of 3 nM [21]. This inhibitor 
(also known as pumpkin seed Hageman factor inhibitor) does 
not inhibit kallikrein or thrombin, but weakly inhibits plasmin 
and FXa [22]. In addition, corn contains a 112 residue inhibitor 
known to inhibit only trypsin and FXIIa [23]. Plasma kallikrein 
is also reversibly inhibited by bovine basic pancreatic trypsin 
inhibitor (BPTI, aprotinin), which also inhibits plasmin and a 
number of other serine proteases and has been used to treat 
patients with acute pancreatitis and during cardiopulmonary 
bypass [24,25]. Replacement of the Ptlysine residue with argin- 
ine resulted in a mutant BPTI having a K~ of 15 nM for kal- 
likrein, which was 20-fold higher affinity than with BPT! itself 
[26]. It is interesting tonote that the active site binding loop of 
BPTI from P2 to P~ is reported to be isostructural with the 
binding loop of ecotin [15]. 
3.6. Implications 
The physiological role of ecotin remains unknown. However, 
since ecotin does not inhibit any known E. coli proteases, its 
location in the periplasm has suggested a role in protecting the 
bacteria from proteases found in the mammalian gut [7]. The 
inhibition of the pancreatic enzymes which are present in the 
mammalian gastrointestinal tract supports this hypothesis. The 
potent inhibition of FXIIa, plasma kallikrein, and FXa by 
ecotin was unexpected and is somewhat more difficult o ration- 
alize. In addition, ecotin potently inhibited HLE, a serine pro- 












Fig. 5. Cleavage of ecotin by FXIIa and kallikrein and reactive site 
determination. Samples were incubated as described inthe text for 48 h 
at room temperature, duced, run on 16% Tricine gels and blotted onto 
PVDF. Lane I = ecotin; lane 2 = ecotin with FXIIa; lane 3 = ecotin 
with kallikrein; lane 4 = kallikrein; lane 5 = FXIIa; and lanes 6 and 
7 = molecular weight markers from Novex and LKB, respectively, with 
the associated M r values x 10 3. Arrows indicate the bands which were 
later excised from the blot and sequenced. The amino-terminal se- 
quence of the lower bands in lanes 2 and 3 (~6.2 kDa) were MA-P; the 
amino-terminal sequence ofthe upper bands in lanes 2 and 3 (~ 8.2 kDa) 
was AESVQ and corresponded to the amino-terminus of ecotin. 
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tease found in azurophilic granules of neutrophils, which is 
released upon activation and has been implicated in the prote- 
olytic destruction of connective tissue proteins and the patho- 
genesis of a variety of inflammatory disorders [27]. A variety 
of serine proteases including FXa, FXIIa, kallikrein, and HLE 
become activated or released uring septic shock [3,4]. Inhibi- 
tion of FXa blocks DIC, however it does not prevent shock or 
organ damage [28]. Conversely, inhibition of FXI Ia can prevent 
hypotension, but does not block DIC [29]. Since ecotin potently 
inhibits FXa, FXIIa, and kallikrein as well as HLE, it is tempt- 
ing to speculate that ecotin, a protein derived from E. coli, may 
provide an effective tool for studying and potentially modulat- 
ing the lethal effects of Gram-negative bacteria induced septice- 
mia. 
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